Table 1.

Summary of results reported from CD19 CAR T-cell pediatric clinical trials

Study	Initial CR%	Initial CR% (ITT)	6-month EFS%	6-month RFS%	6-month OS%	12-month EFS%	12-month RFS%	12-month OS%
Maude et al (2014)23	90	n.a.	67	n.a.	78	n.a.	n.a.	n.a.
Maude et al (2016)44	93	n.a.	70a	76	n.a.	45a	55	79
Maude et al (2018)45	81	66	73	80	90	50	59	76
Gardner et al (2017)52	93	89	n.a.	n.a.	n.a.	50.8	n.a.	69.5
Lee et al (2015) (KTE-C19)42	n.a.	61	n.a.	78.8b	n.a.	n.a.	n.a.	51.6c

Notes:

^aData from Maude et al. 2015 report on 53/59 patients;44

^b4.8 months;

^c10 months.

Abbreviations: CAR, chimeric antigen receptor; CR, complete remission; EFS, event-free survival; ITT, intent to treat; RFS, relapse-free survival; OS, overall survival; n.a., not applicable.